Filtros de búsqueda

Lista de obras de Angelo Di Leo

1st International consensus guidelines for advanced breast cancer (ABC 1).

artículo científico

3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

artículo científico publicado en 2002

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma

scientific article published on 01 July 1996

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

artículo científico publicado en 2000

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients

artículo científico publicado en 2018

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

artículo científico publicado en 2016

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

artículo científico publicado en 2019

A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.

artículo científico publicado en 2015

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer

artículo científico publicado en 2014

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

scientific article published on 16 October 2019

Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer

artículo científico publicado en 1995

Adenocarcinoma of unknown primary site with bone marrow and orbital metastases suggestive of a prostatic origin

artículo científico publicado en 1992

Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer

artículo científico publicado en 1998

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

scientific article published on 26 November 2018

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

artículo científico

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

artículo científico publicado en 2008

Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?

artículo científico publicado en 2009

An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis

scientific article published on 01 December 1995

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

article

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

artículo científico publicado en 2019

Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.

artículo científico publicado en 2008

Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98.

artículo científico publicado en 2013

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

artículo científico publicado en 2018

Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer

artículo científico publicado en 1995

Breast cancer assessment tools and optimizing adjuvant therapy.

scientific article published on 26 October 2010

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

artículo científico publicado en 1997

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

artículo científico publicado en 2014

Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma

scientific article published on 01 December 2001

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

artículo científico

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

scientific article published on 29 July 2021

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

artículo científico

Chemotherapy for metastatic breast cancer.

artículo científico publicado en 2004

Chemotherapy with or without trastuzumab.

artículo científico publicado en 2010

Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.

artículo científico

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

artículo científico publicado en 2008

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

scientific article published on 01 January 1996

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

artículo científico publicado en 2019

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

artículo científico publicado en 2017

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

artículo científico publicado en 1995

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.

artículo científico publicado en 2013

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

artículo científico publicado en 2002

Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

article

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

artículo científico

Control of emesis by a low dose of ondansetron and dexamethasone

scientific article published on 01 April 1994

Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.

artículo científico publicado en 2002

Controversies in the adjuvant treatment of breast cancer: the role of taxanes.

artículo científico publicado en 2004

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

artículo científico publicado en 2006

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

artículo científico publicado en 2020

Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer

article

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

artículo científico publicado en 2009

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

artículo científico publicado en 2019

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.

artículo científico publicado en 2014

DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.

artículo científico publicado en 2013

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.

artículo científico publicado en 2017

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

artículo científico publicado en 2017

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

artículo científico publicado en 2018

Defining breast cancer intrinsic subtypes by quantitative receptor expression

artículo científico publicado en 2015

Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes

artículo científico

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients

artículo científico publicado en 2015

Dissecting the heterogeneity of triple-negative breast cancer

artículo científico

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

artículo científico publicado en 2019

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

scientific article published on 01 February 1999

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

scientific article published on 16 July 2019

Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study

scientific article published on 01 April 1998

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

artículo científico publicado en 2015

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

artículo científico publicado en 1995

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

artículo científico publicado en 1994

Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.

artículo científico publicado en 1995

Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma

scientific article published on 01 January 1993

Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer

scientific article published on 01 November 2019

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

artículo científico publicado en 2009

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

artículo científico publicado en 2001

Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?

artículo científico publicado en 2012

Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study

artículo científico publicado en 2012

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

artículo científico publicado en 2004

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report

artículo científico publicado en 2006

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

artículo científico publicado en 2013

Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing

artículo científico publicado en 2015

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

artículo científico publicado en 2015

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

artículo científico publicado en 2013

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

artículo científico publicado en 2012

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

artículo científico publicado en 2018

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.

artículo científico publicado en 2011

Future perspectives of docetaxel (Taxotere) in front-line therapy.

artículo científico publicado en 1997

Generalized B-cell non Hodgkin's lymphoma in association with leukocytoclastic vasculitis and disseminated intravascular coagulation

artículo científico publicado en 2006

Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial

artículo científico publicado en 2020

Guidelines on the standards for the training of specialised health professionals dealing with breast cancer

article

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

artículo científico publicado en 2004

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice

artículo científico publicado en 2002

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

artículo científico publicado en 2011

HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

artículo científico publicado en 2000

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

artículo científico publicado en 2014

Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?

artículo científico publicado en 2013

Hormone therapy in advanced breast carcinoma: present and future trends.

artículo científico publicado en 1994

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

artículo científico publicado en 2011

Immune Infiltration in Invasive Lobular Breast Cancer

artículo científico publicado en 2018

In Reply to Belkacemi and Tsoutsou

scientific article published on 01 October 2018

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

artículo científico publicado en 2012

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

artículo científico publicado en 2004

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

artículo científico publicado en 2015

Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.

artículo científico publicado en 2008

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

artículo científico publicado en 2019

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

artículo científico publicado en 2017

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

scientific article published on 10 December 2018

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

artículo científico publicado en 2017

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

scientific article published on 23 July 2019

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification

scientific article published on 29 August 2019

Metabolomics in breast cancer: A decade in review

article

Metabolomics: available results, current research projects in breast cancer, and future applications.

artículo científico publicado en 2007

Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group

artículo científico publicado en 1994

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

artículo científico publicado en 2012

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

artículo científico publicado en 1994

Multifactorial approach to predicting resistance to anthracyclines

artículo científico publicado en 2011

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

artículo científico publicado en 2012

Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer

artículo científico publicado en 2016

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

artículo científico publicado en 2018

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial

scientific article published on 27 December 2018

New approaches for improving outcomes in breast cancer in Europe

artículo científico

New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.

artículo científico publicado en 2007

No pain, no gain… What we can learn from a trial reporting negative results

artículo científico publicado en 2017

Ode to a past emperor

scientific article published on 17 May 2010

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

artículo científico publicado en 1995

Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†

artículo científico publicado en 2013

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

artículo científico publicado en 2003

Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer

scientific article published on 01 April 1998

Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.

artículo científico publicado en 1999

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

artículo científico publicado en 2018

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?

artículo científico publicado en 2018

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

scientific article published on 11 February 2019

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

scientific article published on 01 September 1996

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

artículo científico publicado en 2008

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

artículo científico

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

scientific article published on 14 January 2020

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

artículo científico publicado en 2011

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

artículo científico publicado en 2018

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature

artículo científico publicado en 2018

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven

artículo científico publicado en 2012

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

scientific article published on 01 June 2005

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial

artículo científico publicado en 2018

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also

artículo científico publicado en 2015

Predicting anthracycline benefit: have we made any progress?

artículo científico publicado en 2009

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

artículo científico publicado en 2002

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

artículo científico publicado en 2009

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

artículo científico publicado en 2012

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

artículo científico publicado en 2013

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

artículo científico publicado en 2018

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

scientific article published on 03 May 2019

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy

artículo científico publicado en 2014

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

artículo científico publicado en 2019

RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial.

artículo científico publicado en 2017

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

artículo científico publicado en 2004

Re-searching anthracycline therapy

artículo científico publicado en 2010

Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

scientific article published on 03 April 2009

Recurrence dynamics of breast cancer according to baseline body mass index

artículo científico publicado en 2017

Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes.

artículo científico publicado en 2016

Resistance to trastuzumab: a necessary evil or a temporary challenge?

artículo científico publicado en 2002

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

artículo científico publicado en 2010

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.

artículo científico publicado en 2010

Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools

artículo científico publicado en 2017

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast c

artículo científico publicado en 2003

Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?

artículo científico publicado en 2007

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer

artículo científico publicado en 2016

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population

artículo científico publicado en 2017

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

artículo científico publicado en 2014

Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.

artículo científico publicado en 2010

Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.

artículo científico publicado en 2008

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer

artículo científico publicado en 2013

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

artículo científico publicado en 2014

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

artículo científico publicado en 2018

Targeting triple negative breast cancer: is p53 the answer?

artículo científico

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

scientific article published on 08 December 2009

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy

artículo científico publicado en 2019

The European experience with docetaxel in the treatment of early-stage breast cancer.

artículo científico publicado en 2002

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

artículo científico publicado en 1997

The continued evidence from overviews: what is the clinical utility?

artículo científico publicado en 2013

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

artículo científico publicado en 2010

The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and [...]

artículo científico publicado en 2002

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

artículo científico publicado en 2000

The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.

artículo científico publicado en 1994

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review

artículo científico publicado en 2019

The role of abemaciclib in treatment of advanced breast cancer.

artículo científico publicado en 2018

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

scientific article published on 15 September 2009

The state of HER-2 status

artículo científico publicado en 2007

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

artículo científico publicado en 2008

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

artículo científico publicado en 1993

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.

artículo científico publicado en 1993

Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.

artículo científico

Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome

artículo científico publicado en 1999

Using CTCs for pharmacogenomic analysis

artículo científico publicado en 2016

Using specific cytotoxics with a targeted mind.

artículo científico publicado en 2007

[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]

artículo científico publicado en 2008

[Promising new drugs in the treatment of ovarian cancer, and of gynecologic tumors, in general]

scientific article published on 01 May 1999

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data

artículo científico publicado en 2018

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

article

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda